AlphaMark Advisors’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

AlphaMark Advisors’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-93,928	Closed	-$1.69M	–	541
2017 Q4	$1.69M	Sell	93,928 -4,472	-5%	-$55.1K	0.66%	43
2017 Q3	$1.16M	Hold	98,400	–	–	0.49%	46
2017 Q2	$1.03M	Buy	98,400 +19,900	+25%	+$203K	0.44%	51
2017 Q1	$864K	Buy	+78,500	New	+$911K	0.4%	62

Other funds holding SCMP

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AIM

Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

AlphaMark Advisors's SCMP Position: Q1 2018 in Review

AlphaMark Advisors sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 93,928 shares — an estimated $1.69M sold.

AlphaMark Advisors first reported a position in SCMP in Q1 2017 and held it in 4 quarters. The position peaked at $1.69M in Q4 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

AlphaMark Advisors reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
AlphaMark Advisors sold 93,928 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $1.69M.
AlphaMark Advisors first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2017 and held it in 4 quarters.
AlphaMark Advisors's Sucampo Pharmaceuticals, Inc. position peaked at $1.69M in Q4 2017.
3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on AlphaMark Advisors's 13F filing for Q1 2018, filed 9 May 2018.